Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 17/20 | 0.57 |
| ▸ | KDM5A | P29375 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | TOP2A | P11388 | 1/20 | 0.47 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.47 |
| ▸ | KDM4A | O75164 | 2/20 | 0.46 |
| ▸ | KDM5C | P41229 | 2/20 | 0.46 |
| ▸ | KDM4B | O94953 | 1/20 | 0.46 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.46 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8196669 | 0.86 | KDM4C (0.56) | KDM4CKDM5AMAPTTOP2ATOP2B | |
| SCHEMBL4936991 | 0.80 | TOP2A (0.58) | MAPTTOP2ATOP2BPARP1KDM4E | |
| SCHEMBL29965486 | 0.80 | TOP2A (0.58) | MAPTTOP2ATOP2BPARP1KDM4E | |
| SCHEMBL4927788 | 0.79 | KDM4C (0.60) | KDM4CKDM5AMAPTKDM5BKDM4E | |
| SCHEMBL20339526 | 0.75 | PARP1 (0.70) | KDM4CKDM5AMAPTPARP1 | |
| SCHEMBL8199597 | 0.75 | KDM4C (0.59) | KDM4CKDM5AMAPTKDM5B | |
| SCHEMBL2814618 | 0.75 | PIN1 (0.54) | KDM4E | |
| SCHEMBL25190918 | 0.75 | QTRT1 (0.61) | KDM4CKDM5AMAPTKDM4AKDM5C | |
| SCHEMBL8279823 | 0.75 | KDM4C (0.68) | KDM4CKDM5AMAPTPARP1KDM4A | |
| SCHEMBL16908336 | 0.75 | KDM4C (0.59) | KDM4CKDM5AMAPTKDM4AKDM5C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7713966-B2 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7713966-B2 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20080261968-A1 | Heterobicyclic metalloprotease inhibitors | GEGE CHRISTIAN | 2008-10-23 | — | — | US | disclosed |
| US-20080261968-A1 | Heterobicyclic metalloprotease inhibitors | GEGE CHRISTIAN | 2008-10-23 | — | — | US | disclosed |
| EP-1740551-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR | Takeda Pharmaceutical Company Limited (JP) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005105760-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261968-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | KDM4C 1011/4885KDM5A 921/4885MAPT 4248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.